Fulcrum Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-10. Between them they name 3 people, with 3 appointments and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Alan Musso, effective 2026-08-07
In light thereof, on August 9, 2026, Fulcrum's Board of Directors appointed Alan Musso, Fulcrum's chief financial officer and principal financial officer, as principal accounting officer, effective August 7, 2026, upon Mr. Tourangeau's departure.
Departing: Greg Tourangeau, Vice President, Finance
On June 10, 2026, Fulcrum and Greg Tourangeau, Fulcrum's Vice President, Finance and principal accounting officer, mutually agreed that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed between Mr. Tourangeau and Fulcrum.
Appointed: Josh Lehrer, Director
On April 23, 2026, the board of directors, or the Board, of Fulcrum, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Josh Lehrer as a member of the Board, with immediate effect.
Appointed: Josh Lehrer
Mr. Lehrer was appointed to serve on the Science & Technology Committee.
Departing: Alan Musso
On April 23, 2026, Alan Musso notified Fulcrum of his intent to retire as chief financial officer and treasurer (and as principal financial officer).
Find people with the same kind of experience as the Vice President, Finance at Fulcrum Therapeutics, Inc., with the record behind each one.
Find candidates like Finance at Fulcrum Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Fulcrum Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Fulcrum Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Fulcrum Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.